Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Cipla
Indian multi-national pharmaceutical and biotechnology company
Related events
- Morgan Stanley reaffirmed an underweight rating and Citigroup restated a sell rating on Handelsbanken, reported by MarketBeat.
- Morgan Stanley and Royal Bank of Canada initiated coverage of Csquare stock on August 10, 2026, setting ratings of overweight and outperform, respectively.
- Morgan Stanley reaffirmed an overweight rating on STMicroelectronics, and Eastern Bank raised its position in the shares.
- Citigroup upgraded Next plc to a buy rating, while Santander and Morgan Stanley also issued rating updates on the company.
- Citigroup restated a buy rating on SAP shares, and Morgan Stanley reiterated an overweight rating on the company.